Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (8774)	6/27/2003 4:33:19 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

>>Is or will it be approved for reimbursement?<< Yes, but likely not all of it. Think of the portion you pay OP as the benefit of not getting an injection from a stranger in a butcher's gown holding a triple-short espresso in one hand and a cigarette in the other. The real $ issue will be if people have to pay the Dr. for an office visit. Or have to wait in the office etc. Pharmacies are the way to go. >>Didn't the Ph III conclude that the benefit was only about 1/2 day and only if taken on or near the first day of symptoms?<< No. The benefit was highly significant protective immunity from lab challenge and community based trials in thousands of patients >>How likely are people to come back to Flumist after a barely noticeable (or possibly not noticeable) first use?<< ???? How likely are people who have had, or who will have, a bad experience with an injection going to seek a nasal innoculation? >>I guess time will tell, Flumist's long term prospects don't appear too promising to me...<< Agree with the first, disagree with the last. Future blockbuster--2005 and on.